Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy
Introduction. We are aware of the risk of late virological relapse (LVR) years after sustained viral response (SVR) by pegylated interferon and ribavirin alfa (PegIFN + RBV) of chronic hepatitis C viral (HCV) infection. We presented three patients with LVR, treated by PegIFN and ribavirin 5 years...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Military Health Department, Ministry of Defance, Serbia
2018-01-01
|
| Series: | Vojnosanitetski Pregled |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2018/0042-84501700015R.pdf |
| _version_ | 1828481258538139648 |
|---|---|
| author | Ružić Maja Fabri Milotka Preveden Tomislav Bačulov Katarina Pete Maria Stojšin Anja |
| author_facet | Ružić Maja Fabri Milotka Preveden Tomislav Bačulov Katarina Pete Maria Stojšin Anja |
| author_sort | Ružić Maja |
| collection | DOAJ |
| description | Introduction. We are aware of the risk of late virological relapse (LVR) years after sustained viral response (SVR) by pegylated interferon and ribavirin alfa (PegIFN + RBV) of chronic hepatitis C viral (HCV) infection. We presented three patients with LVR, treated by PegIFN and ribavirin 5 years after the SVR was established. Case report. We analysed 129 (38.8% female, 61.2% male, mean age 37.02 ± SD 11.99) patients treated for chronic HCV with PegIFN + RBV, with at least 5 years from the establishment of SVR. In addition to the biochemical parameters of liver function, the qualitative HCV RNA polymerase chain reaction (PCR) and the quantitative PCR HCV RNA test were made. Five years after establishing SVR in 2.3% (3/129) of patients, the relapse of HCV infection was registered by qualitative and quantitative PCR HCV RNA assay and all of these patients had additional autoimmune diseases: vasculitis, autoimmune hepatitis, and vasculitis of central nervous system. Conclusion. The existence, but low rate of LVR HCV infection was confirmed, dominantly in patients with additional autoimmune diseases. Due to this SVR after therapy by PegIFN + RBV should be considered as an indicator of successful HCV suppresion, not its complete eradication. |
| first_indexed | 2024-12-11T07:53:43Z |
| format | Article |
| id | doaj.art-fa05c775ea8c43baa44000de3d25f334 |
| institution | Directory Open Access Journal |
| issn | 0042-8450 2406-0720 |
| language | English |
| last_indexed | 2024-12-11T07:53:43Z |
| publishDate | 2018-01-01 |
| publisher | Military Health Department, Ministry of Defance, Serbia |
| record_format | Article |
| series | Vojnosanitetski Pregled |
| spelling | doaj.art-fa05c775ea8c43baa44000de3d25f3342022-12-22T01:15:17ZengMilitary Health Department, Ministry of Defance, SerbiaVojnosanitetski Pregled0042-84502406-07202018-01-0175121233123610.2298/VSP161026015R0042-84501700015RAutoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapyRužić Maja0Fabri Milotka1Preveden Tomislav2Bačulov Katarina3Pete Maria4Stojšin Anja5Clinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad + Faculty of Medicine, Novi SadClinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad + Faculty of Medicine, Novi SadClinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad + Faculty of Medicine, Novi SadClinical Center of Vojvodina, Center for Laboratory Medicine, Novi SadClinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad + Faculty of Medicine, Novi SadClinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad + Faculty of Medicine, Novi SadIntroduction. We are aware of the risk of late virological relapse (LVR) years after sustained viral response (SVR) by pegylated interferon and ribavirin alfa (PegIFN + RBV) of chronic hepatitis C viral (HCV) infection. We presented three patients with LVR, treated by PegIFN and ribavirin 5 years after the SVR was established. Case report. We analysed 129 (38.8% female, 61.2% male, mean age 37.02 ± SD 11.99) patients treated for chronic HCV with PegIFN + RBV, with at least 5 years from the establishment of SVR. In addition to the biochemical parameters of liver function, the qualitative HCV RNA polymerase chain reaction (PCR) and the quantitative PCR HCV RNA test were made. Five years after establishing SVR in 2.3% (3/129) of patients, the relapse of HCV infection was registered by qualitative and quantitative PCR HCV RNA assay and all of these patients had additional autoimmune diseases: vasculitis, autoimmune hepatitis, and vasculitis of central nervous system. Conclusion. The existence, but low rate of LVR HCV infection was confirmed, dominantly in patients with additional autoimmune diseases. Due to this SVR after therapy by PegIFN + RBV should be considered as an indicator of successful HCV suppresion, not its complete eradication.http://www.doiserbia.nb.rs/img/doi/0042-8450/2018/0042-84501700015R.pdfchronic hepatitis Cinterferon alfa-2bribavirintreatment outcomerecurrenceautoimmune diseases |
| spellingShingle | Ružić Maja Fabri Milotka Preveden Tomislav Bačulov Katarina Pete Maria Stojšin Anja Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy Vojnosanitetski Pregled chronic hepatitis C interferon alfa-2b ribavirin treatment outcome recurrence autoimmune diseases |
| title | Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy |
| title_full | Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy |
| title_fullStr | Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy |
| title_full_unstemmed | Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy |
| title_short | Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy |
| title_sort | autoimmune manifestation of hepatitis c virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy |
| topic | chronic hepatitis C interferon alfa-2b ribavirin treatment outcome recurrence autoimmune diseases |
| url | http://www.doiserbia.nb.rs/img/doi/0042-8450/2018/0042-84501700015R.pdf |
| work_keys_str_mv | AT ruzicmaja autoimmunemanifestationofhepatitiscvirusinfectionasariskforlatevirologicalrelapseafterpegylatedinterferonandribavirintherapy AT fabrimilotka autoimmunemanifestationofhepatitiscvirusinfectionasariskforlatevirologicalrelapseafterpegylatedinterferonandribavirintherapy AT prevedentomislav autoimmunemanifestationofhepatitiscvirusinfectionasariskforlatevirologicalrelapseafterpegylatedinterferonandribavirintherapy AT baculovkatarina autoimmunemanifestationofhepatitiscvirusinfectionasariskforlatevirologicalrelapseafterpegylatedinterferonandribavirintherapy AT petemaria autoimmunemanifestationofhepatitiscvirusinfectionasariskforlatevirologicalrelapseafterpegylatedinterferonandribavirintherapy AT stojsinanja autoimmunemanifestationofhepatitiscvirusinfectionasariskforlatevirologicalrelapseafterpegylatedinterferonandribavirintherapy |